BMRN: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/a39d404c-0454-41da-9eae-2067ca6c79ee/","filing_uuid":"a39d404c-0454-41da-9eae-2067ca6c79ee","filing_type":"2A","filing_type_display":"2nd Quarter - Amendment","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/a39d404c-0454-41da-9eae-2067ca6c79ee/print/","filing_document_content_type":"text/html","income":null,"expenses":"340000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jason D. Kaune, Attorney & Agent for Filer","dt_posted":"2026-07-20T17:06:40-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"770 Lindaro Street","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"San Rafael","registrant_state":"CA","registrant_zip":"94901","registrant":{"id":401049958,"url":"https://lda.gov/api/v1/registrants/401049958/","house_registrant_id":42322,"name":"BIOMARIN PHARMACEUTICAL INC.","description":"Develops and commercializes biopharmaceuticals.","address_1":"770 Lindaro Street","address_2":null,"address_3":null,"address_4":null,"city":"San Rafael","state":"CA","state_display":"California","zip":"94901","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JASON KAUNE","contact_telephone":"+1 415-389-6800","dt_updated":"2026-07-31T17:25:51.428415-04:00"},"client":{"id":197314,"url":"https://lda.gov/api/v1/clients/197314/","client_id":12,"name":"BIOMARIN PHARMACEUTICAL INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-04-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65264,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"EDWARD","last_name":"GREISSING","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58876,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"LOWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154578,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"MAYNE","suffix":null,"suffix_display":null},"covered_position":"SENIOR REGULATORY HEALTH CONSULTANT- FOOD & DRUG ADMINISTRATION (6/2020-2/2022); REGULATORY POLICY ANALYST- FOOD & DRUG ADMINISTRATION (9/2023-6/2024)","new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65264,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"EDWARD","last_name":"GREISSING","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154578,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"MAYNE","suffix":null,"suffix_display":null},"covered_position":"SENIOR REGULATORY HEALTH CONSULTANT- FOOD & DRUG ADMINISTRATION (6/2020-2/2022); REGULATORY POLICY ANALYST- FOOD & DRUG ADMINISTRATION (9/2023-6/2024)","new":true},{"lobbyist":{"id":58876,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"LOWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAR","general_issue_code_display":"Tariff (miscellaneous tariff bills)","description":"GENERAL DISCUSSIONS REGARDING TARDE","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58876,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"LOWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"GENERAL DISCUSSIONS REGARDING CLINICAL TRIAL MODERNIZATION","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":154578,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"MAYNE","suffix":null,"suffix_display":null},"covered_position":"SENIOR REGULATORY HEALTH CONSULTANT- FOOD & DRUG ADMINISTRATION (6/2020-2/2022); REGULATORY POLICY ANALYST- FOOD & DRUG ADMINISTRATION (9/2023-6/2024)","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}